trending Market Intelligence /marketintelligence/en/news-insights/trending/JIX4RL7Q4wdtut7zJFt3Ww2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Ionis, Akcea's Waylivra reduces fat levels to control rare lipid disease

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Ionis, Akcea's Waylivra reduces fat levels to control rare lipid disease

Ionis Pharmaceuticals Inc. and its affiliate Akcea Therapeutics Inc. said their drug Waylivra helped patients with a rare lipid disorder control fat levels in a late-stage study.

Familial partial lipodystrophy, or FPL, which is characterized by abnormal fat distribution, leads to high levels of fat in the liver and muscle, as well as the bloodstream. Patients with the disease can also show a host of metabolic abnormalities, and the conditions can lead to problems with other organs, as well, leading to serious complications, according to Ionis and Akcea.

In initial results from the phase 3 study called BROADEN, patients with FPL showed a significant reduction in fat levels compared to patients taking a placebo. The patients showed 88% reduction in triglyceride levels, which is fat stored in the blood.

Waylivra, which is an antisense drug that targets genetic material to interrupt disease-causing protein creation, reached its secondary goal of reducing liver fat by more than half.

Waylivra gained European approval in May for another lipid disorder called familial chylomicronemia syndrome. The U.S. Food and Drug Administration had previously rejected the drug in August 2018.